These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31655611)

  • 1. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
    Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
    Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.
    Rasti A; Madjd Z; Abolhasani M; Mehrazma M; Janani L; Saeednejad Zanjani L; Asgari M
    Clin Exp Med; 2018 May; 18(2):177-190. PubMed ID: 29204790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and clinical value of SALL4 in renal cell carcinomas.
    Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
    Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD10+ and CK7/RON- immunophenotype distinguishes renal cell carcinoma, conventional type with eosinophilic morphology from its mimickers.
    Yasir S; Herrera L; Gomez-Fernandez C; Reis IM; Umar S; Leveillee R; Kava B; Jorda M
    Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):454-61. PubMed ID: 22417859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
    Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
    Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma.
    Xu H; Xu WH; Ren F; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    Aging (Albany NY); 2020 Jan; 12(1):866-883. PubMed ID: 31915310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
    Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
    Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-mesenchymal transition associated markers in sarcomatoid transformation of clear cell renal cell carcinoma.
    Čugura T; Boštjančič E; Uhan S; Hauptman N; Jeruc J
    Exp Mol Pathol; 2024 Aug; 138():104909. PubMed ID: 38876079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis].
    Wang Y; Hou MY; Fu Y; Meng K; Wu HY; Chen J; Xu YM; Shi J; Fan XS
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):358-363. PubMed ID: 36973196
    [No Abstract]   [Full Text] [Related]  

  • 12. Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
    Iakymenko OA; Delma KS; Jorda M; Kryvenko ON
    Int J Surg Pathol; 2021 Sep; 29(6):600-605. PubMed ID: 33764165
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature.
    Nallandhighal S; Vince R; Karim R; Groves S; Stangl-Kremser J; Russell C; Hu K; Pham T; Cani AK; Liu CJ; Zaslavsky A; Mehra R; Cieslik M; Morgan TM; Palapattu GS; Udager AM; Salami SS
    Eur Urol Oncol; 2022 Feb; 5(1):92-99. PubMed ID: 34840106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel biomarkers to distinguish clear cell and non-clear cell renal cell carcinoma using bioinformatics and machine learning.
    Panwoon C; Seubwai W; Thanee M; Sangkhamanon S
    PLoS One; 2024; 19(6):e0305252. PubMed ID: 38857246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential?
    Horstmann M; Geiger LM; Vogel U; Schmid H; Hennenlotter J; Kuehs U; Merseburger AS; Kruck S; Stenzl A; Bedke J
    World J Urol; 2012 Aug; 30(4):525-31. PubMed ID: 21928123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
    Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
    BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
    Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
    BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.
    Gasinska A; Jaszczynski J; Adamczyk A; Janecka-Widła A; Wilk W; Cichocka A; Stelmach A
    Folia Histochem Cytobiol; 2018; 56(4):195-206. PubMed ID: 30569446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.